Searched for mydecine com latest? The answer depends on which Mydecine you mean, because in 2026 the website and the company behind the name have gone separate ways.
Mydecine.com now runs a general wellness blog. Mydecine Innovations Group Inc., the psychedelic drug developer that listed the domain as its website as late as October 2025, now trades as Noveris Health Sciences Inc. We read the site, the company’s press releases and its exchange bulletins, then lined up what each one says.
Mydecine com Latest Updates at a Glance
The short version, with the source behind each answer.
| Question | Short answer | Based on |
|---|---|---|
| What is on Mydecine.com now? | A wellness blog about physical health, mental health and preventive care, plus many unrelated posts | Mydecine.com homepage, October 2026 |
| Who writes it? | Bylines read Lena Reed, Sienna Ward and “admin”. | |
| The site does not say who runs it | Mydecine.com posts | What happened to Mydecine Innovations Group Inc.? | Renamed Noveris Health Sciences Inc. on 3 February 2026, with the new symbol NVRS | CSE bulletin, 2 February 2026 | Where is the company based? | Vancouver, British Columbia | Company press releases | What is the latest company news? | A patent allowance and restarted lab work in August 2026, a debenture offer of up to $500,000 and an annual meeting on 4 September 2026 | Noveris press releases | Where does the company post news now? | noveris.health | Noveris press releases, 2026 |
Prefer to watch? Here is the short version, in under a minute and a half.
What Mydecine.com Shows Today
Open Mydecine.com today and you land on a WordPress magazine with three main sections: Physical Health, Mental Health and Preventive Care. The footer carries a 2026 copyright line for “MyDecine” and nothing else about who is behind it: no company name, no address and no filings.
Many posts have nothing to do with drug research. Recent titles include “Licensed Casinos With a Focus on High-Payout and High-RTP Games”, “10 Columbia Personal Injury Lawyers to Consider After an Accident” and “Find The Ideal Online Vape Stores Serving Quebec’s Community”.
- Bylines. Lena Reed, Sienna Ward and “admin”.
- Oldest post. The earliest entry in the site’s public post feed is a fitness article dated 8 May 2025.
- Outbound promotion. A “We Recommend” strip sends readers to betting and casino websites.
- Name mash-ups. Titles such as “Zethazinco Island: Exploring Mydecine’s Hidden Paradise In 2026” attach the Mydecine name to unrelated topics.
The Latest Updates section
The site’s own “Latest Updates” archive is the closest match to a mydecine com latest search. It holds 133 posts across 13 pages and shows no publish dates. Its first page mixes dental care, spine care and insurance guides with reviews of lookalike domains such as “My-Decine-Care.com” and “MyDecineCare.com”.
Note. None of the Mydecine.com pages we read mentions Noveris, the 2025 trading restrictions or the 2026 name change.
What Mydecine Innovations Group Inc Was Built to Do
Mydecine Innovations Group developed psychedelic and entactogen medicines. Wikipedia describes it as founded in 2020 in Denver, Colorado, with headquarters in Vancouver, British Columbia.
Its pipeline used MYCO numbers: psilocybin programs MYCO-001 and MYCO-003, a patch-delivered tryptamine called MYCO-004, a psilocin analogue called MYCO-005, an MDMA-like entactogen called MYCO-002, and shorter-acting MDMA-based molecules called MYCO-006 and MYCO-007.
- A mycology lab in Denver
- A Health Canada dealer’s licence for work with mushroom compounds
- A Phase 2A PTSD study with listed sites in Canada and the Netherlands
- Seven patent applications
Those details come from an investor profile on Psychedelic Finance, which still lists http://mydecine.com as the company’s website.
From NewLeaf Brands to Mydecine
The listed company came before the Mydecine name. In April 2020, NewLeaf Brands Inc. agreed to buy Colorado-based Mydecine Group for USD 850,000, paid in NewLeaf shares, and later took the Mydecine Innovations Group name. That likely explains why some stock databases give a founding year of 2013 while Wikipedia says 2020.
Mydecine Innovations Group Timeline From 2020 to 2026
Read in order, the dates show the company and the domain drifting apart.
- April 2020. NewLeaf Brands agrees to buy Mydecine Group.
- December 2020. Mydecine announces plans for the first legal import of psilocybin mushrooms into Canada.
- August 2022. Green Market Report says the company is “Down To $300k In Cash”. New funding keeps it running.
- December 2022. Mydecine closes the sale of its Mindleap Health subsidiary.
From delisting to a new name
From 2025 the pace picks up, and the website stops matching the company.
- 21 March 2025. The company says its shares will leave the Aquis Stock Exchange on 2 April 2025, while staying on the CSE, the US over-the-counter market and Frankfurt.
- 1 May 2025. The British Columbia Securities Commission grants a management cease trade order after the 2024 annual filings run late.
- 8 May 2025. The oldest post in Mydecine.com’s public feed, a fitness article, is dated this day.
- 1 October 2025. Shareholders approve debt settlements paid in convertible debentures, including about CAD 1.3 million in unpaid fees owed to then-CEO Josh Bartch and about CAD 7.9 million owed to Pioneer Garage Limited.
- 21 October 2025. Shares begin trading after a 1-for-50 consolidation.
- 3 February 2026. Mydecine Innovations Group Inc. becomes Noveris Health Sciences Inc. on the CSE, symbol NVRS.
- 10 March 2026. Joshua Bartch resigns as director, president and CEO. Jason Birmingham, chief strategy officer since 2 February 2026, takes all three roles.
- August 2026. Mydecine.com publishes a run of posts presenting “Mydecine” as an active psychedelic biotech, with no mention of Noveris.
Good to know. The company’s May and October 2025 press releases still listed www.mydecine.com as its website. The domain’s public feed already carried wellness posts dated from 8 May 2025. The 2026 Noveris releases point to noveris.health instead.
The Latest Mydecine News Now Comes From Noveris
Since the rename, company news carries the Noveris Health Sciences name and the noveris.health address. The releases are datelined Vancouver and name Jason Birmingham as CEO.
| Date | What the company announced |
|---|---|
| 27 May 2026 | A master services agreement with Applied Pharmaceutical Innovation (API), an Alberta life sciences organization, takes effect |
| 29 June 2026 | Annual meeting set for 4 September 2026, plus a CSE notice on continued listing requirements. |
| Without proof of compliance by the nine-month financial statements to 30 September 2026, the shares get an inactive “.X” designation | |
| 30 July 2026 | Joins BioAlberta, which the release says is not a partnership, financing or endorsement |
| 18 August 2026 | US patent office notice of allowance for six claims on aza-substituted psilocin analogs, and a $146,000 work order with API to restart synthesis of previously investigated compounds |
| 20 August 2026 | Proposed private placement of up to $500,000 in 10% convertible debentures for working capital, overheads and research |
| 4 September 2026 | Annual meeting approves all resolutions and elects Jason Birmingham, Michael Callas and Peter Field as directors |
What the restart covers
As of October 2026, the restarted work is early research to decide next steps. In the CEO’s words, the company is “putting selected compounds back into active research”.
Note. Under the work order, API handles the chemistry to make the earlier compounds again, in vitro testing in the lab, and quality and project management. The release presents this as groundwork for deciding which compounds go further.
What Mydecine.com Says Versus the Company Record
No other page we found sets these side by side. Several 2026 posts on Mydecine.com describe “Mydecine” as an active psychedelic biotech, so we compared their claims with the company’s own releases and exchange bulletins.
| Mydecine.com post | Published | Byline | What it says | What the record shows |
|---|---|---|---|---|
| Inside Mydecine Innovation Drive, Toronto (M5V 2K1) | 9 Aug 2026 | Lena Reed | Calls Mydecine “a leading research campus” that “sits in downtown Toronto” | Releases are datelined Vancouver, and stock listings give a West Georgia Street, Vancouver address |
| Mydecine FT Asia Money Playbook | 9 Aug 2026 | Lena Reed | The board keeps “a cash buffer equal to several quarters of planned spend” | Debts settled in convertible debentures in late 2025, then a 2026 offer of up to $500,000 for working capital |
| Mydecine.com Explained | 15 Aug 2026 | Lena Reed | Presents Mydecine.com as “The Psychedelic Biotech Site” | The company’s 2026 releases list noveris.health as its website |
| Mydecine Uncovered | 15 Aug 2026 | Lena Reed | Says it “runs Phase 1 safety studies and Phase 2 efficacy trials” | The August 2026 release describes restarting synthesis and lab testing of earlier compounds, and announces no trial |
Where the stories split
- Location. Toronto on the blog, Vancouver in every company release we read.
- Name. The blog never mentions Noveris. The exchange renamed the company in February 2026.
- Research. The blog describes running trials. The company describes restarting lab work.
- Money. The blog describes a cash buffer. The company’s releases describe debt settlements and new convertible financing.
- Sources. None of the four posts cites a filing, a press release or a study.
Tip. For anything about the company, trust the most recent exchange bulletin or press release over the domain. In 2026 that means Noveris Health Sciences releases.
Where the Mydecine Name Still Appears
The old name lives on in several places, and some of them still send readers to Mydecine.com. As of October 2026:
- Mydecine.com. A wellness blog with no company filings, contacts or press releases.
- Company press releases. Issued as Noveris Health Sciences, with noveris.health as the website.
- Canadian Securities Exchange. Listed as Noveris Health Sciences Inc., symbol NVRS.
- US over-the-counter market. Still quoted under the old symbol MYCOF.
- Wikipedia. Still titled Mydecine and lists mydecine.com as the website.
- Investor profile sites. Some still show the Mydecine name, older tickers and http://mydecine.com.
Mydecine.com and the Lookalike Names
The name now covers a drug developer, its former domain and a growing list of lookalikes. The blog itself reviews “My-Decine-Care.com” and “MyDecineCare.com”, and attaches the Mydecine name to topics from gaming fridges to an island called Zethazinco.
| Mydecine Innovations Group Inc. | ||
|---|---|---|
| Mydecine.com today | ||
| What it is | Psychedelic drug developer, now Noveris Health Sciences Inc. | |
| Wellness and lifestyle blog | ||
| Based in | Vancouver, British Columbia | Not stated |
| Website used | noveris.health in 2026, www.mydecine.com in 2025 releases | mydecine.com |
| Publishes | Press releases and exchange filings | Health guides, reviews and unrelated posts |
| Mentions the other | Not in any 2026 release we read | Writes about “Mydecine” but never about Noveris |
How to Check Any Company’s Latest Updates
Mydecine is a clear case of a name, a domain and a company parting ways. These steps catch it early.
- Start with the exchange. Search the company or its symbol on the exchange’s website. Name and symbol changes appear there as bulletins.
- Read the footer of the latest press release. The website listed there is the one the company stands behind today.
- Check the filings database. Canadian issuers file on SEDAR+. Look at the date of the latest financial statements.
- Compare the domain with the releases. If a site never mentions recent releases, treat it as a separate publisher.
- Watch for renamed symbols. An old symbol can live on in the US over-the-counter market after a rename.
- Discount pages without sources. A post that names no filing, release or study is opinion, whatever domain it sits on.
Questions Readers Ask About Mydecine Innovations Group
Is Mydecine.com still the company’s website?
Not in practice. The company’s 2026 releases list noveris.health. Mydecine.com runs a wellness blog that does not mention Noveris, and we found no company statement about the domain.
What is Mydecine Innovations Group Inc called now?
Noveris Health Sciences Inc. The Canadian Securities Exchange changed the name and the symbol, from MYCO to NVRS, effective 3 February 2026.
What is the latest Mydecine news?
The most recent items we found are an August 2026 notice of allowance from the US patent office, a work order with Applied Pharmaceutical Innovation, a proposed private placement of up to $500,000 and the 4 September 2026 annual meeting.
Who runs Mydecine now?
Jason Birmingham. He became chief strategy officer on 2 February 2026 and took over as president, CEO and director when Joshua Bartch resigned on 10 March 2026.
Is Mydecine still developing psilocybin medicines?
In August 2026 the company said it was putting selected compounds back into active research, starting with synthesis and lab testing at API. Its patent allowance covers aza-substituted psilocin analogs. The releases we read announce no new clinical trial.
Is Mydecine stock still trading?
Yes, as Noveris Health Sciences on the CSE under NVRS and in the US over-the-counter market under MYCOF. A June 2026 CSE notice warned of an inactive designation if the company cannot show it meets continued listing requirements. This is not investment advice.
Bottom Line on Mydecine.com and Mydecine
Anyone searching mydecine com latest now finds two separate stories, and they no longer come from the same place. The domain publishes general wellness and unrelated content, while the drug developer behind the name became Noveris Health Sciences in February 2026 and reports through noveris.health.
For company news, follow Noveris releases and CSE bulletins. For Mydecine.com, read each post on its own merits and check any company claim against those primary sources.
